The impact of bilberry extract combined with docosahexaenoic acid on the expression of Chrnb4 gene in the sclera of myopic guinea pigs.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Frontiers in Medicine Pub Date : 2025-06-04 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1590362
Mei-Hong Zhu, Qian Wen, Tai-Nan Lin, Yun Gao, Xiao-Ting Liu, Jing-Hua Lin, Miao Lin, Qiao-Mei Shi
{"title":"The impact of bilberry extract combined with docosahexaenoic acid on the expression of Chrnb4 gene in the sclera of myopic guinea pigs.","authors":"Mei-Hong Zhu, Qian Wen, Tai-Nan Lin, Yun Gao, Xiao-Ting Liu, Jing-Hua Lin, Miao Lin, Qiao-Mei Shi","doi":"10.3389/fmed.2025.1590362","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the therapeutic potential of bilberry extract combined with docosahexaenoic acid (DHA) in myopia management by examining their effects on Chrnb4 gene expression in the sclera of lens-induced myopic guinea pigs and elucidating the underlying regulatory mechanisms, thereby providing a theoretical foundation for the development of natural active component-based myopia prevention and treatment strategies.</p><p><strong>Methods: </strong>One hundred twenty guinea pigs were systematically allocated into five experimental groups: normal control (NC), lens-induced myopia (LIM), LIM+DHA, LIM+bilberry extract (LIM+BE), and LIM+DHA+BE. Myopia was experimentally induced through the application of -6.0D lenses. The intervention groups received daily administrations of DHA (100 mg/kg), bilberry extract (16.5 mg/kg), or their combination for a duration of 12 weeks. Ocular parameters including refractive status and axial length were quantified using a handheld refractometer and A-scan ultrasound, respectively. Choroidal thickness (ChT) and choroidal vascularity index (CVI) were evaluated through swept-source OCT imaging. Molecular analyses encompassing Chrnb4 expression, dopamine concentrations, and TGF-β/MMP-2/TIMP-1 pathway components were conducted using immunofluorescence, ELISA, and Western blot techniques.</p><p><strong>Results: </strong>Following 4 weeks of myopia induction, the LIM group demonstrated significant myopic changes, including reduced refraction (-3.75 ± 1.35 D), decreased ChT (89.00 ± 10.37 μm), increased axial length (11.33 ± 1.67 mm), and diminished CVI (22.64 ± 4.91%) compared to NC group (all <i>P</i> < 0.001). After 12 weeks of therapeutic intervention, the combined treatment group showed marked improvements in ocular parameters, with refraction measuring -2.46 ± 0.92 D and axial length reduced to 9.94 ± 1.10 mm. Notably, ChT and CVI increased by 8.7 and 15.6%, respectively, compared to the LIM group (<i>P</i> < 0.05). Molecular analysis revealed significant upregulation of Chrnb4 protein expression, elevation of dopamine levels to 41.13 ± 1.58 nmol/g, suppression of TGF-β and MMP-2 expression, and enhancement of TIMP-1 levels (all <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>The combination of bilberry extract and DHA demonstrates significant efficacy in controlling myopia progression through multiple mechanisms, including upregulation of Chrnb4 gene expression, modulation of the TGF-β/MMP-2/TIMP-1 signaling pathway, and enhancement of dopamine levels. These findings collectively contribute to the inhibition of scleral remodeling and axial elongation. This study provides valuable insights for the development of novel, multi-targeted natural therapeutic approaches for myopia prevention and treatment.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1590362"},"PeriodicalIF":3.1000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12174452/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1590362","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aimed to investigate the therapeutic potential of bilberry extract combined with docosahexaenoic acid (DHA) in myopia management by examining their effects on Chrnb4 gene expression in the sclera of lens-induced myopic guinea pigs and elucidating the underlying regulatory mechanisms, thereby providing a theoretical foundation for the development of natural active component-based myopia prevention and treatment strategies.

Methods: One hundred twenty guinea pigs were systematically allocated into five experimental groups: normal control (NC), lens-induced myopia (LIM), LIM+DHA, LIM+bilberry extract (LIM+BE), and LIM+DHA+BE. Myopia was experimentally induced through the application of -6.0D lenses. The intervention groups received daily administrations of DHA (100 mg/kg), bilberry extract (16.5 mg/kg), or their combination for a duration of 12 weeks. Ocular parameters including refractive status and axial length were quantified using a handheld refractometer and A-scan ultrasound, respectively. Choroidal thickness (ChT) and choroidal vascularity index (CVI) were evaluated through swept-source OCT imaging. Molecular analyses encompassing Chrnb4 expression, dopamine concentrations, and TGF-β/MMP-2/TIMP-1 pathway components were conducted using immunofluorescence, ELISA, and Western blot techniques.

Results: Following 4 weeks of myopia induction, the LIM group demonstrated significant myopic changes, including reduced refraction (-3.75 ± 1.35 D), decreased ChT (89.00 ± 10.37 μm), increased axial length (11.33 ± 1.67 mm), and diminished CVI (22.64 ± 4.91%) compared to NC group (all P < 0.001). After 12 weeks of therapeutic intervention, the combined treatment group showed marked improvements in ocular parameters, with refraction measuring -2.46 ± 0.92 D and axial length reduced to 9.94 ± 1.10 mm. Notably, ChT and CVI increased by 8.7 and 15.6%, respectively, compared to the LIM group (P < 0.05). Molecular analysis revealed significant upregulation of Chrnb4 protein expression, elevation of dopamine levels to 41.13 ± 1.58 nmol/g, suppression of TGF-β and MMP-2 expression, and enhancement of TIMP-1 levels (all P < 0.05).

Conclusion: The combination of bilberry extract and DHA demonstrates significant efficacy in controlling myopia progression through multiple mechanisms, including upregulation of Chrnb4 gene expression, modulation of the TGF-β/MMP-2/TIMP-1 signaling pathway, and enhancement of dopamine levels. These findings collectively contribute to the inhibition of scleral remodeling and axial elongation. This study provides valuable insights for the development of novel, multi-targeted natural therapeutic approaches for myopia prevention and treatment.

越桔提取物联合二十二碳六烯酸对近视豚鼠巩膜Chrnb4基因表达的影响。
目的:本研究旨在通过观察越橘提取物联合二十二碳六烯酸(DHA)对晶状体性近视豚鼠巩膜Chrnb4基因表达的影响,探讨其治疗近视的潜力,并阐明其潜在的调控机制,为开发基于天然活性成分的近视防治策略提供理论基础。方法:将120只豚鼠系统分为正常对照组(NC)、晶状体性近视组(LIM)、LIM+DHA组(LIM+BE)、LIM+越橘提取物组(LIM+BE)和LIM+DHA+BE 5个实验组。实验采用-6.0D晶状体诱导近视。干预组每天给予DHA (100 mg/kg)、越橘提取物(16.5 mg/kg)或两者的组合,持续12周。使用手持式屈光计和a扫描超声分别定量测定眼参数,包括屈光状态和眼轴长度。通过扫描源OCT成像评估脉络膜厚度(ChT)和脉络膜血管指数(CVI)。采用免疫荧光、ELISA和Western blot技术对Chrnb4表达、多巴胺浓度和TGF-β/MMP-2/TIMP-1通路组分进行分子分析。结果:诱导近视4周后,与NC组相比,LIM组的屈光度降低(-3.75±1.35 D), ChT降低(89.00±10.37 μm),眼轴长度增加(11.33±1.67 mm), CVI降低(22.64±4.91%)(均P < 0.001)。治疗干预12周后,联合治疗组眼参数明显改善,屈光度-2.46±0.92 D,眼轴长度减少至9.94±1.10 mm。与LIM组相比,ChT和CVI分别增加了8.7和15.6% (P < 0.05)。分子分析显示,Chrnb4蛋白表达上调,多巴胺水平升高至41.13±1.58 nmol/g, TGF-β和MMP-2表达抑制,TIMP-1水平升高(均P < 0.05)。结论:越桔提取物与DHA联用可通过上调Chrnb4基因表达、调节TGF-β/MMP-2/TIMP-1信号通路、提高多巴胺水平等多种机制调控近视进展。这些发现共同有助于抑制巩膜重塑和轴向伸长。本研究为开发新的、多靶点的近视预防和治疗方法提供了有价值的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信